Brokerages forecast that TESARO, Inc. (NASDAQ:TSRO) will announce $121.33 million in sales for the current quarter, according to Zacks. Eight analysts have issued estimates for TESARO’s earnings. The lowest sales estimate is $33.60 million and the highest is $162.60 million. TESARO posted sales of $3.73 million during the same quarter last year, which suggests a positive year-over-year growth rate of 3,152.8%. The company is scheduled to report its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that TESARO will report full year sales of $121.33 million for the current year, with estimates ranging from $108.10 million to $280.80 million. For the next year, analysts forecast that the business will report sales of $482.17 million per share, with estimates ranging from $312.94 million to $636.60 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that follow TESARO.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm’s quarterly revenue was down 17.6% on a year-over-year basis. During the same period last year, the business posted ($1.28) earnings per share.

A number of analysts have weighed in on the company. Gabelli assumed coverage on TESARO in a report on Friday, July 7th. They set a “buy” rating and a $175.00 price target for the company. Credit Suisse Group set a $190.00 price target on TESARO and gave the stock a “buy” rating in a report on Friday, August 18th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $235.00 price target on shares of TESARO in a report on Sunday, August 20th. Cann reiterated a “buy” rating and set a $199.00 price target on shares of TESARO in a report on Friday, September 8th. Finally, Citigroup Inc. reiterated a “buy” rating and set a $216.00 price target on shares of TESARO in a report on Monday, September 11th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $170.19.

Shares of TESARO (TSRO) opened at 116.40 on Friday. The firm’s market capitalization is $6.31 billion. TESARO has a 52 week low of $106.64 and a 52 week high of $192.94. The company’s 50 day moving average price is $120.86 and its 200-day moving average price is $132.79.

In other TESARO news, SVP Martin H. Jr. Huber sold 592 shares of TESARO stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the transaction, the senior vice president now owns 6,943 shares in the company, valued at approximately $823,439.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James O. Armitage sold 10,000 shares of TESARO stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $1,171,300. The disclosure for this sale can be found here. Insiders have sold a total of 35,692 shares of company stock valued at $4,628,976 in the last quarter. Company insiders own 40.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Exane Derivatives acquired a new position in TESARO during the 3rd quarter valued at about $106,000. Botty Investors LLC bought a new position in shares of TESARO during the 2nd quarter worth approximately $140,000. Nordea Investment Management AB bought a new position in shares of TESARO during the 2nd quarter worth approximately $167,000. Oppenheimer Asset Management Inc. lifted its position in shares of TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares in the last quarter. Finally, BB&T Securities LLC bought a new position in shares of TESARO during the 2nd quarter worth approximately $222,000.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/22/121-33-million-in-sales-expected-for-tesaro-inc-tsro-this-quarter.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.